Shemesh Shay
SEC CIK 1896056 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | Chief Development Off | 1.79M | $94.5K | — | 17 | 2022-02-04 | 2026-01-06 |
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-06 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +150.0K | 1.79M | +9% | $0 | |
| 2025-01-03 | 2025-01-02 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +150.0K | 1.64M | +10% | $0 | |
| 2024-05-13 | 2024-05-10 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $6.32 | +1,113 | 1.49M | +0.1% | +$7,034 | |
| 2024-01-05 | 2024-01-03 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +130.0K | 1.49M | +10% | $0 | |
| 2023-03-22 | 2023-03-21 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $11.99 | +420 | 1.36M | +0.0% | +$5,036 | |
| 2023-03-17 | 2023-03-15 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $10.71 | +670 | 1.36M | +0.0% | +$7,176 | |
| 2023-01-13 | 2023-01-12 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +115.0K | 1.36M | +9% | $0 | |
| 2022-12-22 | 2022-12-21 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $7.65 | +500 | 1.25M | +0.0% | +$3,825 | |
| M | 2022-11-18 | 2022-11-16+ | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $7.15 | +300 | 1.25M | +0.0% | +$2,145 |
| 2022-09-27 | 2022-09-23 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $7.87 | +220 | 1.25M | +0.0% | +$1,731 | |
| 2022-09-06 | 2022-09-02 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $8.31 | +404 | 1.24M | +0.0% | +$3,357 | |
| M | 2022-09-02 | 2022-08-31+ | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $8.07 | +3,006 | 1.24M | +0.2% | +$24.3K |
| 2022-05-23 | 2022-05-20 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $16.54 | +300 | 1.24M | +0.0% | +$4,962 | |
| M | 2022-05-18 | 2022-05-16+ | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $19.44 | +242 | 1.24M | +0.0% | +$4,704 |
| M | 2022-05-13 | 2022-05-12 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $15.85 | +1,278 | 1.24M | +0.1% | +$20.3K |
| 2022-04-05 | 2022-04-01 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +60.0K | 1.24M | +5% | $0 | |
| M | 2022-02-08 | 2022-02-04+ | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Development Off | P - Purchase | $3.41 | +2,946 | 1.18M | +0.3% | +$10.0K |
Purchase Sale Sale after option exercise All abbreviations